Comparison study of the effect of alkyl-modified and unmodified PAMAM and PPI dendrimers on solubility and antitumor activity of crocetin
Source abstract
Abstract
Poor water solubility of hydrophobic drugs is one of the major problems in pharmaceutical sciences. Herein, in order to address the poor solubility of crocetin, the 30% of primary amines of PAMAM G4 and PPI G4 were alkylated and evaluated as drug delivery vectors. According to the results, this modification could improve the drug delivery efficiency in term of drug solubility, release pattern and cytotoxicity; however, the encapsulation yield was decreased. Accordingly, it can be concluded that the designed alkylated dendrimers are able to improve the drug delivery efficiency, may be through improving the solubility and cellular uptake of crocetin.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Saffron Plant Research Studies · Biological Activity of Diterpenoids and Biflavonoids · Flavonoids in Medical Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;
Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran;
Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran;
Department of Biotechnology, Higher Education Institute of Rab-Rashid, Tabriz, Iran;
Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
References (36)
Show source-provided references
1. 10.1016/j.pbb.2005.06.00710.1016/j.pbb.2005.06.007 ↗
2. 10.1177/088532821559966710.1177/0885328215599667 ↗
3. 10.1002/(SICI)1521-3773(20000403)39:7<1285::AID-ANIE1285>3.0.CO;2-F10.1002/(SICI)1521-3773(20000403)39:7<1285::AID-ANIE1285>3.0.CO;2-F ↗
4. 10.3109/10520295.2014.89074110.3109/10520295.2014.890741 ↗
5. 10.1016/S0040-4020(03)00437-X10.1016/S0040-4020(03)00437-X ↗
6. 10.2174/13892001079111083610.2174/138920010791110836 ↗
7. 10.1111/nyas.1281610.1111/nyas.12816 ↗
8. 10.1080/1061186040001065510.1080/10611860400010655 ↗
9. 10.3109/10837450.2011.65382210.3109/10837450.2011.653822 ↗
10. 10.2174/13892011279886856610.2174/138920112798868566 ↗
11. 10.1080/21691401.2016.119835910.1080/21691401.2016.1198359 ↗
12. 10.1208/s12249-015-0284-210.1208/s12249-015-0284-2 ↗
13. Hashemi M · Nanomed J · 2013 · 1 · 55
14. 10.1517/17425255.4.8.103510.1517/17425255.4.8.1035 ↗
15. 10.3109/03639045.2014.90007710.3109/03639045.2014.900077 ↗
16. 10.1021/jf062638l10.1021/jf062638l ↗
17. 10.1139/bcb-2013-009110.1139/bcb-2013-0091 ↗
18. 10.1002/ptr.266610.1002/ptr.2666 ↗
19. 10.1021/bm050614210.1021/bm0506142 ↗
20. 10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
21. Mukerjee A · Anticancer Res · 2009 · 29 · 3867
22. 10.1517/17425247.2013.80195710.1517/17425247.2013.801957 ↗
23. 10.1016/j.ejphar.2010.09.00310.1016/j.ejphar.2010.09.003 ↗
24. 10.1016/j.ejphar.2012.06.03510.1016/j.ejphar.2012.06.035 ↗
25. 10.1002/jgm.137410.1002/jgm.1374 ↗
26. 10.1006/jcis.2001.778710.1006/jcis.2001.7787 ↗
27. 10.1021/bc070014v10.1021/bc070014v ↗
28. 10.1016/0304-3835(95)03964-X10.1016/0304-3835(95)03964-X ↗
29. 10.2174/15672021280041083010.2174/156720212800410830 ↗
30. 10.1093/carcin/12.3.45910.1093/carcin/12.3.459 ↗
31. 10.1007/s10856-013-4969-310.1007/s10856-013-4969-3 ↗
32. 10.3724/SP.J.1009.2009.0022310.3724/SP.J.1009.2009.00223 ↗
33. 10.1016/j.ijpharm.2011.09.04410.1016/j.ijpharm.2011.09.044 ↗
34. 10.1111/j.2042-7158.2010.01184.x10.1111/j.2042-7158.2010.01184.x ↗
35. 10.1016/j.biomaterials.2011.11.07810.1016/j.biomaterials.2011.11.078 ↗
36. 10.1016/j.ijpharm.2013.04.07510.1016/j.ijpharm.2013.04.075 ↗